Collects blood and tissue samples from people with HIV or related cancers
Collects blood and tumor samples from adults with HIV, KSHV infection, or related cancers.
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
- Status
- Recruiting
- People taking part
- 1,029 people, planned
- Started
- 6 Dec 2000
- Type of study
- Observational
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with HIV, KSHV, EBV or HTLV-1 infection, or at risk of them. It also looks for people with cancer, Castleman's disease or certain lesions. Samples of blood, fluids and tissue are collected.
- Age
- 18 years or older (up to 120 years).
- Sex
- Women and men can join.
- Disease stage
- At least one of these is needed: HIV, KSHV, EBV or HTLV-1 positive blood test; cancer, Castleman's disease or skin lesions that look like Kaposi's sarcoma; or a cervical or anal intraepithelial lesion. Exposure risk to HIV, KSHV or HPV also counts. ECOG performance status 3 or lower.
- Biomarker or test result
- Positive blood test (seropositive) for HIV, KSHV, EBV or HTLV-1. A past positive test or a past KSHV-linked disease is enough.
The registry criteria, word for word
Show all 12 criteriaShow less
Who cannot take part
- None
Other criteria
- INCLUSION CRITERIA:
- Age 18 years or older
- ECOG performance status less than or equal to 3; At least one of the following:
- Exposure risk to HIV, KSHV, or HPV
- HIV seropositive
- KSHV seropositive
- EBV seropositive
- HTLV-1 seropositive; NOTE: infection with HIV, KSHV, EBV, and HTLV-1 are life-long, so if participants have previously been seropositive or have had a disease associated with KSHV (KS, primary effusion lymphoma [PEL], or KSHV-multicentric Castleman s disease [MCD]), this is sufficient to meet this criterion for eligibility
- Malignancy, MCD, or skin lesions with appearance of KS
- Cervical or anal intraepithelial lesion
- Ability of participant to understand and the willingness to sign a written informed consent document
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 120 years old?
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: Ijeoma M AgwuTaking people
About the trial
What the trial wants to find out
BACKGROUND:
Read full original descriptionShow less
* A number of important scientific advances can be made through the study of blood, bone marrow, tumor, or other tissue samples from patients with HIV infection, infection with Kaposi s sarcoma associated herpesvirus (KSHV), infection with other oncogenic viruses, or cancer. * This protocol provides a mechanism to affect a variety of such studies.
OBJECTIVES:
-Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples from participants with HIV infection, KSHV infection, or with cancer.
ELIGIBILITY:
-Eligibility criteria include age 18 years or older and at least one of the following: Exposure risk to HIV, KSHV, or HPV; HIV seropositive; KSHV seropositive; EBV seropositive; HTLV-1 seropositive; malignancy, Castleman s disease, or skin lesions with appearance of Kaposi s sarcoma; or cervical or anal intraepithelial lesion.
DESIGN:
* Up to 999 subjects will be enrolled in this study. * Blood samples may be collected at the initial visit, and at follow-up visits. * Other fluids/excretions may be collected (such as urine, saliva, semen, and stool). * Tumor samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal fluid, by skin punch biopsy, or by excisional biopsy, providing the tumor is accessible with minimal risk to the participants. * Specific risks will be described in a separate consent to be obtained at the time of the biopsy. * Samples will be studied in the HIV and AIDS Malignancy Branch, CCR, NCI; laboratories in NCI-Frederick; or those of collaborating investigators.
The group in the trial
- 1
Participants with HIV infection, KSHV infection, or with cancer
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer
- Plain-language title
- Collects blood and tissue samples from people with HIV or related cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT00006518, who can take part
- Publications
- Kaposi Sarcoma Herpesvirus (KSHV) Subtypes and Impact on Outcomes in KSHV-Associated Diseases.The Journal of infectious diseases, 2026
- Inflammasome activation in patients with Kaposi sarcoma herpesvirus-associated diseases.Blood, 2024
- Transcriptional landscape of Kaposi sarcoma tumors identifies unique immunologic signatures and key determinants of angiogenesis.Journal of translational medicine, 2023
- Record updated
- 16 October 2026